On the basis of mass spectral analysis, Mathews et al. [1] claimed that a substance indistinguishable from the plant-derived ouabain was present in human plasma as a plausible endogenous digitalis-Like factor (EDLF) and proposed an indirect ELISA specific for ouabain to detect EDLF [2] . The antisera, raised in rabbits to protein conjugates of commercially available ouabain, demonstrated high specificity for ouabain and closely related cardenolides, with a cross-reactivity of 0.5-5% with digoxin.
Immunoreactive ouabain was found in many organs in the rat [3] and dog [4] (probably produced by adrenals), and was increased in some human disorders, including heart failure [5] and several forms of hypertension [6] . Recent papers [7] [8] [9] , however, have issued some criticism to these findings.
A ouabain enzyme immunoassay (EIA) reagent pack for quantification of ouabam from biological fluids including Hamlyn's antibody has become available in Italy (NEK-072; DuPont-NEN, Boston, MA) [10] . In and 50 p.L of 250 pmol/L '251-labeled digoxin, with or without 100 p.L of ouabain calibrators (freshly prepared from the 10 mmol/L stock solution at concentrations of 10-200 nmol/L) or C18-extracted samples in a total volume of 500 p.L of RRA buffer (per liter, 5 mmol of Na2 HPO4, 5 mmol of MgCI2, 50 mmol of Tris-HC1, pH 7.4, at 37 #{176}C, and 1 g of BSA). Bound and free radioactivity were separated by rapid filtration through glass fiber filters, and retained radioactivity was counted in a gamma spectrometer. Nonspecific binding was assessed in the presence of 10 p.molIL ouabain and was subtracted from the total binding to calculate the specific binding.
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ouabain to the microplate wells, as evaluated by the amount of color generated in the absence of sample or calibrator, progressively decreased for both lots of reagents from >3 A (undetectable by our colorimetric microplate reader) to <0.300 A. No significant intrabatch drift was usually observed, as estimated by measuring the "0" calibrator at the beginning and end of a batch. The speed of addition of the reagents and the batch length, however, were determinant.
Cross-reactivity of digoxin, at least up to 5 nmol/L, was negligible.
The progressive change in the shape of the ouabain ETA calibration curve with the same lot no. of reagents is shown in Fig. lA (Fig. 1C) . This could suggest that the DuPont ouabain ETA can detect in human plasma extracts an endogenous ligand of digitalis receptors; however, some glaring discrepancies need to be pointed out. In two of the healthy adults studied, all plasma specimens (n = 6) read "0" in the ouabain ETA but had bioactivity in the RRA (between 75 and 384 pmoVL), indicating that the EDLF activity in these two subjects was not ouabain. Moreover, other specimens (9 of 71) from different patients had no activity by RRA but had up to 80 pmol/L immunoactivity.
This discrepancy, which may also reflect the major sensitivity of the ouabain ETA as compared with the human placenta RRA, seems to confirm that, in some instances, the two assays are unrelated.
In summary, the DuPont ouabain ETA appeared to be more sensitive than other ouabain immunoassays [8, 9, 13], but assay sensitivity decreased with time and the method did not produce consistent results. Moreover, it required supplementary materials and preparation of assay buffer and ouabain calibrators, which is not well suited to a routine laboratory procedure. Finally, despite the high specificity of the anti-ouabain antibody 12, 10], the assay required extraction of plasma samples, which, as we demonstrated, contributed the most to the overall variability of our RRA [11] . However, the other ouabain immunoassays [2, 4, 7, 8, 13 Our results indicate that most of the activity measured by the human placenta RRA appears to be unrelated to ouabain immunoactivity (even if 10-fold differences for values measured by ETA and RRA are not uncommon) and that the two assays can disagree for a given patient. Nevertheless, discrepant results might also be due to the poor reliability of the immunological method. For now, efforts to improve the usefulness of an assay for detecting mammalian EDLF would be better directed at standardization of assay procedures than at devising more assays. Given its current variability, we believe that this DuPont reagent pack may not be suitable for measuring circulating ouabain in routine clinical laboratories or for clinical trials.
